OncoResponse Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 24
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $40.6M
Latest Deal Amount
  • Investors
  • 21

OncoResponse General Information

Description

Developer of therapeutic antibodies intended for the treatment of cancer. The company leverages a proprietary B-cell technology platform to develop cancer immunotherapies (therapeutic antibodies) against immuno-oncology targets by interrogating the human immune system, enabling doctors and patients to optimally combat cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Primary Office
  • 1124 Columbia Street
  • Suite 300
  • Seattle, WA 98104
  • United States
+1 (206) 000-0000

OncoResponse Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoResponse Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 25-Mar-2021 $40.6M 00000 00000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 14-Jun-2019 0000 000.00 0000 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 23-Mar-2017 $29.5M $29.5M 0000 Completed Pre-Clinical Trials
1. Joint Venture 18-Aug-2015 Completed Pre-Clinical Trials
To view OncoResponse’s complete valuation and funding history, request access »

OncoResponse Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.00
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 29,499,000 $0.001000 $0.06 $1 $1 1x $1 20.32%
To view OncoResponse’s complete cap table history, request access »

OncoResponse Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic antibodies intended for the treatment of cancer. The company leverages a proprietary B-cell tec
Drug Discovery
Seattle, WA
24 As of 2021
00000
0000 0000-00-00
00000000000 00000

0000 000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
0000 000000000
Amsterdam, Netherlands
0 As of 0000
000.00
0000000000 0 000.00

00000000

sse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000000000000
Saint Louis, MO
0 As of 0000
000.00
0000 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoResponse Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AIMM Therapeutics Venture Capital-Backed Amsterdam, Netherlands 0 000.00 0000000000 0 000.00
000000000000000 Venture Capital-Backed Saint Louis, MO 0 000.00 00000000000 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000 00000000000 Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
You’re viewing 5 of 20 competitors. Get the full list »

OncoResponse Executive Team (6)

Name Title Board Seat Contact Info
Clifford Stocks Co-Founder, Chief Executive Officer & Board Member
Kamal Puri Chief Scientific Officer
Robert Lechleider MD Chief Medical Officer
You’re viewing 3 of 6 executive team members. Get the full list »

OncoResponse Board Members (11)

Name Representing Role Since
Clifford Stocks OncoResponse Co-Founder, Chief Executive Officer & Board Member 000 0000
Daguang Wang Ph.D Yonjin Venture Board Member 000 0000
John Mckearn Ph.D RiverVest Venture Partners Board Member 000 0000
Patrick Hojlo Qatar Investment Authority Board Member 000 0000
Roberto DePonti Helsinn Healthcare Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

OncoResponse Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoResponse Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bering Capital Venture Capital Minority 000 0000 000000 0
Magnetar Capital Hedge Fund Minority 000 0000 000000 0
Yonjin Venture Corporate Venture Capital Minority 000 0000 000000 0
Buchang Pharmaceutical Other Minority 000 0000 000000 0
Qatar Investment Authority Sovereign Wealth Fund Minority 000 0000 000000 0
You’re viewing 5 of 21 investors. Get the full list »

OncoResponse Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 07-Nov-2017 000000000000000000 Biotechnology 00000000 000000
To view OncoResponse’s complete acquisitions history, request access »